You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥AH股齊拉昇 業績超預期
格隆匯10月25日丨國內臨牀CRO龍頭泰格醫藥A股一度漲超9%報178.98元,H股一度漲近5%報158港元;泰格醫藥目前市值逼近1500億元人民幣。公司日前公吿,2021年第三季度收入13.39億元,同比增57.77%,淨利5.26億元,同比增64.80%;前三季度收入33.95億,同比增47.58%,淨利17.81億元,同比增35.13%。光大證券點評稱,泰格醫藥業績超預期,Q3營收環比增速進一步提升,表明臨牀CRO業務增長強勁,疫情影響逐步衰退。與Q2相比,Q3銷售費用率2.17%,管理費用率10.68%,均出現下滑,表明公司運營效率提升,行業內品牌度良好。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.